







































LOH = loss of heterozygosity.
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Introduction
A few years ago, a fascinating article by Deng et al [1]
showed loss of heterozygosity (LOH) on chromosome 3p
in apparently normal breast tissue adjacent to a carci-
noma. Evidence was presented to show that the carci-
noma also showed 3p loss. The importance accorded to
these findings was reflected by their publication in
Science. Readers inferred that 3p loss may sometimes be
an early event in breast tumorigenesis that might have pro-
duced a selective advantage and clonal expansion, but led
to no change in morphology. This model of tumorigenesis
was therefore subtly different from that proposed for the
pathogenesis of colorectal tumours, in which even the ear-
liest lesions were morphologically distinct from normal
tissue [2].
Lakhani  et al [3] studied short-term cultures of luminal
epithelial and myoepithelial breast cells derived from
macroscopically normal fresh breast tissue adjacent to
carcinoma. This method was used to exclude the possibil-
ity that the ‘normal’ tissue studied by Deng et al [1] might
actually have been heavily contaminated by cancer cells
that had undergone Pagetoid spread. Microdissected
normal duct-lobular units were also analysed, thus provid-
ing a direct comparison with the study of Deng et al [1].
Five of 13 cases showed some LOH in normal tissue,
although this was variable in its origin (microdissected or
cultured, adjacent to cancer or distant from cancer). Loss
was seen in normal tissue, most often at markers near
BRCA2 on chromosome 13q and rarely at markers on
chromosome 3p near those studied by Deng et al [1].
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The accumulation of mutations is a feature of all normal cells. The probability of any individual gene in
any cell acquiring a mutation is, however, low. Cancer is therefore a rare disease in comparison with
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have accumulated in the cell of origin prior to tumorigenesis. Despite some claims to the contrary, even
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Loss in normal tissue was not always observed in any
adjacent carcinoma.
No large sample series has ever confirmed the existence
of detectable mutations in apparently normal breast tissue
(perhaps no one has tried) and each of the two studies
above had potential technical problems, which were
almost unavoidable. The ability of polymerase chain reac-
tion to produce consistent, artefactual allelic loss, espe-
cially in archival samples, is becoming increasingly well
documented. In vitro selection may be strong in short-term
culture and result in outgrowth of occasional cells with
mutations unrelated to tumorigenesis in vivo. It would nev-
ertheless be wrong to dismiss the findings of Deng et al
[1] or those of Lakhani et al [3] on the grounds that they
are uninteresting, unimportant or simply incorrect. On the
contrary, the topic of mutations in normal tissues not only
is associated with precursor lesions for breast tumours,
but also is potentially important for studies of patch size
and the presence of normal, clonal cell populations in the
breast, and for the number and significance of mutations
subsequently found in breast tumours that develop from
those tissues.
Allelic loss and clonal origins of normal breast
An important consideration when analysing mutations in
normal tissue using molecular techniques is that any allelic
loss in normal tissue must either have led to some expan-
sion of that clone or must have occurred before normal
clonal expansion; otherwise, the genetic change would
not be detectable using standard methods. Strictu sensu
allelic loss can thus not truly be detected in normal tissue
unless the progenitor cell has undergone clonal expan-
sion. The topic of clonal expansion in normal breast, and
hence patch size, is a vexed one. Given that breast prolif-
eration occurs relatively late in development, human breast
tissue may ultimately be derived from few stem cells,
leading to exceptionally large patch size and consequent
problems for studies of monoclonality in breast tumours.
Moreover, any genetic change that occurred in the breast
prior to puberty would probably be manifest as a
detectable (clonal) mutation in normal adult breast tissue,
and an unwarranted significance might be ascribed to that
mutation. There is unfortunately very little evidence con-
cerning patch size in the normal breast, owing to the diffi-
culties inherent in such an analysis [4]. Distinguishing
between this explanation for the data of Deng et al [1] and
the alternative explanation (that the ‘normal’ tissue is actu-
ally an early neoplasm) is not currently possible.
Mutations in normal breast tissue
The results of Deng et al [1] serve another useful purpose,
which is to highlight the often neglected fact that lots of
mutations occur continuously in all normal cells at normal
rates of mutation. How many mutations might occur in the
normal breast epithelial stem cell in a 10-year period?
Assuming that the normal mutation rate is 1.4 × 10–9 per
nucleotide per cell division, that a diploid genome has
1010 bases and that the cell undergoes 50 divisions per
year, then 7000 mutations would occur. Almost all of
these mutations will have no functional effect, because
they occur in ‘junk’ DNA (or, more rarely, diploidy protects
against functional consequences). Tumours thus arise only
exceptionally because at least ‘two hits’ usually have to
occur somatically in the same gene, and the chances of
this are very small. If a breast tumour does happen to
arise, however, it starts to grow with many thousands of
mutations that have already been acquired by the cell of
origin during normal tissue development and maintenance.
Recent surprise that cancers have as many as 10,000
mutations [5,6] is thus entirely misplaced: the tumour
progenitor cell may already have this many mutations
before any genetic changes occur during tumorigenesis.
How many mutations in a cancer?
It is often claimed that normal mutation rates are too low to
account for changes in the five or six genes generally sup-
posed to be mutated, as a minimum, for a cancer to occur
[7]. It is thus argued that all cancers must have some form
of genomic instability, probably from an early stage. This
reasoning is based on a simple calculation. Loeb [7] stated
that “if the mutation rate is normally 1.4 × 10–9 per
nucleotide per cell division and that per gene is 2.0 × 10–7,
a [stem] cell with a genome of 70,000 genes will accumu-
late one mutant gene during an individual’s lifetime …
assuming 100 cell divisions in a normal lifespan”.
Let us take Loeb’s calculation as stated, even though some
stem cells almost certainly divide many thousands of times
in a 65-year period, Loeb’s statement ignores the crucial
question of how the cell acquires genomic instability. To
inactivate three tumour suppressor genes and to activate
three oncogenes requires a total of nine mutations. Making
no allowance for the fact that LOH is probably more fre-
quent than small intragenic mutations, simple calculations
show that the probability of a cell acquiring any one of
these mutations is about 4 × 10–5 and that the probability
of acquiring all nine mutations is about 10–40.
Even if there are many millions of stem cells in any tissue
and the lifetime risk of breast cancer is 10%, the probabil-
ity of developing a cancer would thus be minuscule
according to this model. Crucially, however, the simple
model takes no account of clonal expansion [8]. The
simple calculation assumes that the stem cell simply waits
to acquire mutations. The best evidence suggests,
however, that a stepwise model of tumorigenesis, in which
successive advantageous mutations lead to successive
rounds of clonal expansion, is a much more likely scenario
[9]. The probability of a cancer acquiring sufficient muta-
tions is thus much higher than that in Loeb’s calculation,







































tumour clone have a chance of acquiring mutations.
Clonal expansion is not simply a facet of tumorigenesis
that allows mutations to occur; on the contrary, clonal
expansion is tumorigenesis, driven by selection.
A simulation model of stepwise tumorigenesis illustrates
how powerful clonal selection can be by, in effect, raising
the mutation rate through increasing population size. In
this simulation, it is assumed that a stem cell has already
acquired ‘two hits’ at a tumour suppressor locus. From
Loeb’s parameters, the probability of this happening for
any individual cell during an individual lifetime is about
5×1 0 –10. This probability may seem low for a common
cancer, but it should not be forgotten that the probability
of a stem cell acquiring genomic instability by, for example,
inactivating a DNA repair gene, is similarly low. Moreover,
each tissue may have many millions of stem cells and
there may be several different genes that can cause
cancer when mutated. Hence, the effective mutation rate
may actually be much higher than that calculated from
Loeb’s parameters.
The mutant clone with only ‘two hits’ initially expands rela-
tively slowly. It is assumed that mutation of three onco-
genes and one further tumour suppressor are required to
give a cancer; the incorporation of extra genes makes the
model impracticably complex. Each activation of an onco-
gene or inactivation of the tumour suppressor gene
confers an additional selective advantage, as long as the
necessary mutations earlier in the pathway have already
occurred in that cell. Although a detailed analysis is inap-
propriate here, typical results of the simulation are shown
in Figure 1. It is clear that clonal expansion results in the
growing tumour having more than sufficient time to
acquire all the necessary mutations (three oncogenes and
two more at a tumour suppressor locus) in this model
within a realistic time. Given that the tumour is very large,
the extra mutations required in Loeb’s suggested six-locus
model will also almost certainly occur within a realistic
time. The first mutations in tumorigenesis are indeed the
rate-limiting step here.
Normal mutation rates are thus quite sufficient to explain
the crucial mutations needed to drive tumorigenesis, but
how many mutations exist within a typical cancer? Even at
normal mutation rates, it can be calculated that a cancer
will contain many billions of mutations (data not shown),
and that millions of these mutations will be present in a
large enough proportion of the tumour to be readily
detectable using standard molecular techniques. Most




Model of clonal evolution and mutation in cancer, run as a simulation with a typical result shown. For the starting point of the model, a single cell is
assumed to have acquired two mutations at a tumour suppressor locus (A), and thereby to have acquired a small replicative advantage (here, 1.01
per generation). The simulation subsequently allows mutation to occur at random in each tumour cell at oncogene loci B, D and E and at tumour
suppressor locus C, at a constant rate of 2 × 10–7 per gene per generation. The selective advantage associated with activation of B is 1.05. The
advantage associated with biallelic inactivation of C is 5.0, as long as B is already mutated. The advantage associated with D activation is 20.0, as
long as B and C are mutated. The advantage associated with activation of E is 100, as long as B, C and D are all already mutated. These
advantages are multiplicative. The lines show numbers of tumour cells at each generation with the ‘genotypes’ A mutant only, A and B both mutant,
A–C mutant, A–D mutant, and A–E all mutant. The results show that a tumour of (nominal) size 1016 cells (y axis is log scale) with all loci mutated is
readily achieved within 1500 cell generations (i.e. 30 years if, conservatively, 50 stem cell generations occur per year). Note: This model greatly
understates the case for the ability of cancers to develop at a normal mutation rate because it assumes only a single genetic pathway of
tumorigenesis and hence a much lower effective mutation rate than exists in reality. Moreover, action of extrinsic carcinogens may also cause the
mutation rate to be raised above the ‘normal’ level.The predicted number of mutations in the typical cancer
seems huge, but it can be accounted for by three factors.
First, most cancers take many years to grow and they
therefore almost certainly undergo many more cell divisions
than the theoretical minimum required to produce a tumour
of the size typically removed by surgery. Second, there is a
tendency to underestimate the huge number of back-
ground mutations, because these rarely occur in regions of
the genome analysed by molecular techniques and they are
not observed consistently in different tumours of the same
type. Finally, the genetic mutations that already exist in the
tumour cell of origin are sometimes forgotten.
The role of genomic instability
Although unnecessary for tumorigenesis, there is evidence
that many cancers are genetically unstable [10]. There are
also good reasons to expect genomic instability to be dis-
advantageous, at least early in tumorigenesis, because
intact cell cycle checkpoints tend to push cells with DNA
damage into apoptosis [11]. Later in tumorigenesis,
however, the advantages of genomic instability may out-
weigh the disadvantages. First, instability might have
occurred by chance, ‘hitch-hiking’ with advantageous
mutations. Second, instability might be directly advanta-
geous. In a large cancer, for example, nutrient supply may
be rate-limiting for growth, which might be almost static;
considerable numbers of cells (up to 50% of all daugh-
ters) would therefore die in each generation. Under this
scenario, genomic instability might confer a net selective
advantage, by compensating for the lack of clonal expan-
sion and producing novel combinations of mutations. This
production may lead, for example, to invasion of surround-
ing tissues or metastasis, while being of relatively little
selective disadvantage, especially if a cell had acquired
cell cycle checkpoint mutations by this stage. Third, a pos-
sibility [11], for which circumstantial evidence is accruing
[12], is that a single mutation (such as a mutation in p53
or APC) may have pleiotropic effects, providing a cancer
cell with both a replicative advantage and an increased
mutation rate. Many connections between DNA repair,
chromosome segregation and the cell cycle have been
discovered, and it is easy to see how a defective cell cycle
checkpoint could lead both to faster replication and to tol-
erance of accumulated mutations.
Types of genomic instability are best characterized in col-
orectal cancer, where they include microsatellite instability,
a poorly defined phenomenon of ‘chromosomal instability’
and a methylator phenotype. Other types of instability have
been hypothesised, including a ‘translocator phenotype’
and a ‘mitotic recombination phenotype’. Many breast
cancers are aneuploid/polyploid and thus possibly chromo-
somally unstable, and other cancers (largely lobular and
grade I ductal) are near-diploid. Nevertheless, little is
known about the presence and type of genetic instability in
breast tumours. There is some evidence of centrosome
amplification, either as a cause of or consequence of chro-
mosomal instability [13–15], but there is no evidence of
true microsatellite instability (despite some reports) [16,17]
nor, as yet, of a methylator phenotype.
Conclusions
All cells in all organisms are prone to mutations. Presum-
ably, in the soma, the normal frequency of mutation has
arisen as an evolutionary trade-off between the probability
of diseases such as cancer and the costs of an even more
faithful system of replicating DNA and chromosomes.
Normal cells accumulate large numbers of mutations, but
these are rarely of functional importance and rarely
detected unless single-cell methods are used. There is a
tendency for cancer biologists to underestimate the
‘power’ of the normal mutation rate, and to assume that
cancers cannot develop in the absence of genomic insta-
bility. This is not the case and many early tumours, in par-
ticular, show no evidence of a raised mutation rate. It is
nevertheless indisputable that many cancers do have
some form of genomic instability, derived from the disrup-
tion of certain cellular processes, such as DNA repair or
centrosome formation. This genomic instability should
arguably be regarded not as the main driving force of
tumorigenesis, but as an adaptation to specific environ-
mental conditions or, intriguingly, as a pleiotropic effect of
mutations selected primarily for their effects on cell repli-
cation and/or death.
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